Difference between revisions of "Template:Estrogen dosages for menopausal hormone therapy"

From blackwiki
Jump to navigation Jump to search
imported>Medgirl131
imported>Monkbot
m (Task 18a (cosmetic) (manual): eval 13 templates: del empty params (4×); cvt lang vals (1×);)
 
Line 38: Line 38:
 
| [[Subcutaneous implant|{{abbr|SC|Subcutaneous}} implant]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 mg 1x/6 months || 50 mg 1x/6 months || 100 mg 1x/6 months
 
| [[Subcutaneous implant|{{abbr|SC|Subcutaneous}} implant]] || {{No selflink|Estradiol (medication)|Estradiol}} || 25 mg 1x/6 months || 50 mg 1x/6 months || 100 mg 1x/6 months
 
|- class="sortbottom"
 
|- class="sortbottom"
| colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Footnotes:''' <sup>a</sup> = No longer used or recommended, due to health concerns. <sup>b</sup> = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. '''Note:''' Dosages are not necessarily equivalent. '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="KuhlWiegratz2008">{{cite book|last1=Kuhl|first1=Herbert|last2=Wiegratz|first2=Inka|title=Klimakterium, Postmenopause und Hormonsubstitution|trans-title=Climacteric, Postmenopause and Hormone Replacement|edition=4|url=https://www.amazon.de/Klimakterium-Postmenopause-Hormonsubstitution-Herbert-Kuhl/dp/3837420434/|date=1 January 2008|language=German|publisher=UNI-MED-Verlag|isbn=978-3-83742-043-2|page=188}}</ref><ref name="WiegratzKuhl2007">{{cite journal|last1=Wiegratz|first1=I.|last2=Kuhl|first2=H.|title=Praxis der Hormontherapie in der Peri- und Postmenopause|trans-title=Practice of hormone therapy in the peri- and postmenopause|journal=Gynäkologische Endokrinologie|volume=5|issue=3|year=2007|pages=141–149|issn=1610-2894|doi=10.1007/s10304-007-0194-9}}</ref><ref name="pmid18365854">{{cite journal | vauthors = Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW | title = Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause | journal = Climacteric | volume = 11 | issue = 2 | pages = 108–23 | date = April 2008 | pmid = 18365854 | doi = 10.1080/13697130801983921 | url = }}</ref><ref name="Borgelt2010">{{cite book|author=Laura Marie Borgelt|title=Women's Health Across the Lifespan: A Pharmacotherapeutic Approach|url=https://books.google.com/books?id=riP3pxq2jWAC&pg=PA257|year=2010|publisher=ASHP|isbn=978-1-58528-194-7|pages=257–}}</ref><ref name="DiPiroTalbert2017">{{cite book|vauthors= DiPiro JT, Talbert RL, Yee GC,Matzke GR, Wells BG, Posey LM|title=Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition|url=https://books.google.com/books?id=BwF9DQAAQBAJ|date=23 January 2017|publisher=McGraw-Hill Education|isbn=978-1-259-58749-8|page=1295}}</ref><ref name="pmid17290731">{{cite journal | vauthors = Warren MP | title = Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration | journal = Mayo Clin. Proc. | volume = 82 | issue = 2 | pages = 219–26 | date = February 2007 | pmid = 17290731 | doi = 10.4065/82.2.219 | url = }}</ref><ref name="pmid18042008">{{cite journal | vauthors = Simon JA, Snabes MC | title = Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen | journal = Expert Opin Investig Drugs | volume = 16 | issue = 12 | pages = 2005–20 | date = December 2007 | pmid = 18042008 | doi = 10.1517/13543784.16.12.2005 | url = }}</ref><ref name="FritzSperoff2012_Composition">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=KZLubBxJEwEC&pg=PA751|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4847-3|pages=751–753}}</ref><ref name="ThomasKeenan1986">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Ruggiero2002">{{cite journal|last1=Ruggiero|first1=R|title=Estrogen: physiology, pharmacology, and formulations for replacement therapy|journal=Journal of Midwifery & Women's Health|volume=47|issue=3|year=2002|pages=130–138|issn=15269523|doi=10.1016/S1526-9523(02)00233-7}}</ref><ref name="Depo-Estradiol-Label 2005">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf]</ref><ref name="BruntonLazo2005_">{{cite book|author1=Laurence Brunton|author2=John Lazo|author3=Keith Parker|title=Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition|url=https://books.google.com/books?id=PtWdBgnQdjMC|date=13 September 2005|publisher=McGraw Hill Professional|isbn=978-0-07-160891-6|page=1553|quote=These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol.}}</ref><ref name="pmid29693907">{{cite journal|last1=Kutlesic|first1=Ranko|last2=Popovic|first2=Jasmina|last3=Stefanovic|first3=Milan|last4=Vukomanovic|first4=Predrag|last5=Andric|first5=Aleksandra|last6=Milosevic|first6=Jelena|title=Menopausal hormone therapy: Benefits and different forms|journal=Medicinski pregled|volume=69|issue=7-8|year=2016|pages=247–254|issn=0025-8105|pmid=29693907|doi=10.2298/MPNS1608247K}}</ref></noinclude><includeonly>See template.</includeonly>
+
| colspan="8" style="width: 1px; background-color:#eaecf0; text-align: center;" | '''Footnotes:''' <sup>a</sup> = No longer used or recommended, due to health concerns. <sup>b</sup> = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. '''Note:''' Dosages are not necessarily equivalent. '''Sources:''' <noinclude><ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = http://hormonebalance.org/images/documents/Kuhl%2005%20%20Pharm%20Estro%20Progest%20Climacteric_1313155660.pdf}}</ref><ref name="KuhlWiegratz2008">{{cite book|last1=Kuhl|first1=Herbert|last2=Wiegratz|first2=Inka|title=Klimakterium, Postmenopause und Hormonsubstitution|trans-title=Climacteric, Postmenopause and Hormone Replacement|edition=4|url=https://www.amazon.de/Klimakterium-Postmenopause-Hormonsubstitution-Herbert-Kuhl/dp/3837420434/|date=1 January 2008|language=de|publisher=UNI-MED-Verlag|isbn=978-3-83742-043-2|page=188}}</ref><ref name="WiegratzKuhl2007">{{cite journal|last1=Wiegratz|first1=I.|last2=Kuhl|first2=H.|title=Praxis der Hormontherapie in der Peri- und Postmenopause|trans-title=Practice of hormone therapy in the peri- and postmenopause|journal=Gynäkologische Endokrinologie|volume=5|issue=3|year=2007|pages=141–149|issn=1610-2894|doi=10.1007/s10304-007-0194-9}}</ref><ref name="pmid18365854">{{cite journal | vauthors = Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW | title = Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause | journal = Climacteric | volume = 11 | issue = 2 | pages = 108–23 | date = April 2008 | pmid = 18365854 | doi = 10.1080/13697130801983921 }}</ref><ref name="Borgelt2010">{{cite book|author=Laura Marie Borgelt|title=Women's Health Across the Lifespan: A Pharmacotherapeutic Approach|url=https://books.google.com/books?id=riP3pxq2jWAC&pg=PA257|year=2010|publisher=ASHP|isbn=978-1-58528-194-7|pages=257–}}</ref><ref name="DiPiroTalbert2017">{{cite book|vauthors= DiPiro JT, Talbert RL, Yee GC,Matzke GR, Wells BG, Posey LM|title=Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition|url=https://books.google.com/books?id=BwF9DQAAQBAJ|date=23 January 2017|publisher=McGraw-Hill Education|isbn=978-1-259-58749-8|page=1295}}</ref><ref name="pmid17290731">{{cite journal | vauthors = Warren MP | title = Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration | journal = Mayo Clin. Proc. | volume = 82 | issue = 2 | pages = 219–26 | date = February 2007 | pmid = 17290731 | doi = 10.4065/82.2.219 }}</ref><ref name="pmid18042008">{{cite journal | vauthors = Simon JA, Snabes MC | title = Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen | journal = Expert Opin Investig Drugs | volume = 16 | issue = 12 | pages = 2005–20 | date = December 2007 | pmid = 18042008 | doi = 10.1517/13543784.16.12.2005 }}</ref><ref name="FritzSperoff2012_Composition">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=KZLubBxJEwEC&pg=PA751|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4847-3|pages=751–753}}</ref><ref name="ThomasKeenan1986">{{cite book|last1=Thomas|first1=John A.|last2=Keenan|first2=Edward J.|chapter=Estrogens and Antiestrogenic Drugs|pages=135–165|doi=10.1007/978-1-4684-5036-1_7|title=Principles of Endocrine Pharmacology|url=https://books.google.com/books?id=mTagBQAAQBAJ&pg=PA150|date=6 December 1986|publisher=Springer Science & Business Media|isbn=978-1-4684-5036-1}}</ref><ref name="Ruggiero2002">{{cite journal|last1=Ruggiero|first1=R|title=Estrogen: physiology, pharmacology, and formulations for replacement therapy|journal=Journal of Midwifery & Women's Health|volume=47|issue=3|year=2002|pages=130–138|issn=15269523|doi=10.1016/S1526-9523(02)00233-7}}</ref><ref name="Depo-Estradiol-Label 2005">[https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/085470s015lbl.pdf]</ref><ref name="BruntonLazo2005_">{{cite book|author1=Laurence Brunton|author2=John Lazo|author3=Keith Parker|title=Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition|url=https://books.google.com/books?id=PtWdBgnQdjMC|date=13 September 2005|publisher=McGraw Hill Professional|isbn=978-0-07-160891-6|page=1553|quote=These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol.}}</ref><ref name="pmid29693907">{{cite journal|last1=Kutlesic|first1=Ranko|last2=Popovic|first2=Jasmina|last3=Stefanovic|first3=Milan|last4=Vukomanovic|first4=Predrag|last5=Andric|first5=Aleksandra|last6=Milosevic|first6=Jelena|title=Menopausal hormone therapy: Benefits and different forms|journal=Medicinski pregled|volume=69|issue=7-8|year=2016|pages=247–254|issn=0025-8105|pmid=29693907|doi=10.2298/MPNS1608247K}}</ref></noinclude><includeonly>See template.</includeonly>
 
|}<!--
 
|}<!--
  

Latest revision as of 19:09, 16 December 2020

Estrogen dosages for menopausal hormone therapy

Route/form Estrogen Low Standard High
Oral Template:No selflink 0.5–1 mg/day 1–2 mg/day 2–4 mg/day
Template:No selflink 0.5–1 mg/day 1–2 mg/day 2–4 mg/day
Template:No selflink 0.45–0.9 mg/day 0.9–1.8 mg/day 1.8–3.6 mg/day
Template:No selflink 0.3–0.45 mg/day 0.625 mg/day 0.9–1.25 mg/day
Template:No selflink 0.3–0.45 mg/day 0.625 mg/day 0.9–1.25 mg/day
Template:No selflink 0.75 mg/day 1.5 mg/day 3 mg/day
Template:No selflink 1–2 mg/day 2–4 mg/day 4–8 mg/day
Template:No selflinka 2.5 μg/day 5–15 μg/day
Nasal spray Template:No selflink 150 μg/day 300 μg/day 600 μg/day
Transdermal patch Template:No selflink 25 μg/dayb 50 μg/dayb 100 μg/dayb
Transdermal gel Template:No selflink 0.5 mg/day 1–1.5 mg/day 2–3 mg/day
Vaginal Template:No selflink 25 μg/day
Template:No selflink 30 μg/day 0.5 mg 2x/week 0.5 mg/day
IM or SC injection Template:No selflink 4 mg 1x/4 weeks
Template:No selflink 1 mg 1x/3–4 weeks 3 mg 1x/3–4 weeks 5 mg 1x/3–4 weeks
Template:No selflink 0.5 mg 1x/week 1 mg 1x/week 1.5 mg 1x/week
SC implant Template:No selflink 25 mg 1x/6 months 50 mg 1x/6 months 100 mg 1x/6 months
Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: [1][2][3][4][5][6][7][8][9][10][11][12][13][14]
Template documentation

See also

References

  1. Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  2. Kuhl, Herbert; Wiegratz, Inka (1 January 2008). Klimakterium, Postmenopause und Hormonsubstitution [Climacteric, Postmenopause and Hormone Replacement] (in German) (4 ed.). UNI-MED-Verlag. p. 188. ISBN 978-3-83742-043-2.
  3. Wiegratz, I.; Kuhl, H. (2007). "Praxis der Hormontherapie in der Peri- und Postmenopause" [Practice of hormone therapy in the peri- and postmenopause]. Gynäkologische Endokrinologie. 5 (3): 141–149. doi:10.1007/s10304-007-0194-9. ISSN 1610-2894.
  4. Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW (April 2008). "Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause". Climacteric. 11 (2): 108–23. doi:10.1080/13697130801983921. PMID 18365854.
  5. Laura Marie Borgelt (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 257–. ISBN 978-1-58528-194-7.
  6. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (23 January 2017). Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition. McGraw-Hill Education. p. 1295. ISBN 978-1-259-58749-8.
  7. Warren MP (February 2007). "Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration". Mayo Clin. Proc. 82 (2): 219–26. doi:10.4065/82.2.219. PMID 17290731.
  8. Simon JA, Snabes MC (December 2007). "Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen". Expert Opin Investig Drugs. 16 (12): 2005–20. doi:10.1517/13543784.16.12.2005. PMID 18042008.
  9. Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–753. ISBN 978-1-4511-4847-3.
  10. Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
  11. Ruggiero, R (2002). "Estrogen: physiology, pharmacology, and formulations for replacement therapy". Journal of Midwifery & Women's Health. 47 (3): 130–138. doi:10.1016/S1526-9523(02)00233-7. ISSN 1526-9523.
  12. [1]
  13. Laurence Brunton; John Lazo; Keith Parker (13 September 2005). Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition. McGraw Hill Professional. p. 1553. ISBN 978-0-07-160891-6. These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol.
  14. Kutlesic, Ranko; Popovic, Jasmina; Stefanovic, Milan; Vukomanovic, Predrag; Andric, Aleksandra; Milosevic, Jelena (2016). "Menopausal hormone therapy: Benefits and different forms". Medicinski pregled. 69 (7–8): 247–254. doi:10.2298/MPNS1608247K. ISSN 0025-8105. PMID 29693907.